XtalPi and Sunshine Lake Pharma Announce Strategic Collaboration to Advance AI-Driven Drug Discovery with 'AI + Robotics' Paradigm

[Dongguan, January 26] —— Today, XtalPi (hereinafter referred to as “XtalPi”, stock code:2228.HK) has signed a significant strategic cooperation agreement with Guangdong HEC Pharm Co., Ltd. ("HEC Pharm", stock code: 6887), a leading R&D-driven pharmaceutical giant in China. The two parties plan to establish a joint venture, deeply integrating the leading advantages of XtalPi's AI + robotics drug discovery platform with HEC Pharm’s extensive accumulation in multi-target R&D data, biological insights, and pipeline development experience. By jointly building an AI + robotics lab and a large non-clinical drug model, they aim to address many long-standing challenges in drug discovery, achieving comprehensive cooperation in fundamental technologies, new drug pipeline development, and commercialization. In this collaboration, HEC Pharm is expected to invest hundreds of millions of yuan.The two companies willAiming to build an industry-leading AI drug discovery engine and achieve technology export, construct a diversified profit model of "pipeline co-creation + technology win-win".。

As a leading pharmaceutical company in China with the highest number of patents, Dongyang Guangyaoyao boasts real-world data assets for over 150 approved drugs and more than 100 drugs under research. It has industry-leading expertise in biological insights, drug discovery, and development, and continues to invest in the R&D and product transformation of AI-driven pharmaceuticals. XtalPi, as a global leader in intelligent drug research and development platforms, leverages its unique innovative strengths through the deep integration of quantum physics, AI, and robotic experiments. This has enabled the construction of a complete technological chain from virtual design and screening to wet-lab experimental validation. Its partners include 17 of the top 20 global pharmaceutical companies. The collaboration between the two parties is by no means a simple stacking of technologies but rather an extensive partnership covering..."Data-Model-Pipeline-Commercialization"Comprehensive and in-depth collaboration. The two parties will jointly build AI drug discovery models and AI + robotics laboratories to create an industry-leading AI drug discovery engine, and collaborate on developing innovative pipelines for autoimmune diseases.Achieve the dual flywheel effect of "monetizing the technology foundation" and "self-sustaining new drug pipelines" to share in the subsequent commercialization outcomes.

At the infrastructure and technology base level, the two parties will deploy a large-scale robotic experimental workstation cluster at Dongyangguang Pharmaceutical based on XtalPi's technical accumulation in AI algorithms and automated chemistry.Building an AI-Driven Automated Drug Discovery Laboratory, forming an "algorithm prediction - experimental validation" efficient closed loop, and accumulating high-precision, structured real data. Combining Dongyangguang Pharmaceutical's massive non-clinical data with XtalPi's cutting-edge AI algorithms,The Two Parties Plan to Develop an Industry-Leading Physiologically-Based Pharmacokinetic (PB-PK) Large Model, in order to optimize R&D decision-making, reduce R&D risks, and enhance the success rate of subsequent in vivo and clinical trials. The two companies will also build a full life cycle AI drug discovery engine based on the unique advantages accumulated by the joint venture in data, computing power, and models. They will focus on overcoming technical challenges in areas such as difficult-to-drug targets, molecular synthesis, structure-activity relationships, and pharmacokinetics, laying a solid foundation for the continuous value transformation of data assets and the development of innovative drug pipelines.

In terms of commercialization, the two parties will focus on the field of autoimmune diseases, integrating Dongyangguang Pharmaceutical's full-chain expert experience with XtalPi's technical achievements in AI drug research and development.Accelerate the discovery of candidate drugs and their clinical translation.In addition, the two parties will also leverage XtalPi's global commercial network to jointly promote the co-developed PB-PK large model, the full life cycle AI drug discovery engine, as well as Dongyangguang Pharmaceutical's self-developed "HEC-SynAI Drug Synthesis Large Model" and "HEC-PharmAI Formulation Large Model." The two parties will not only share the future benefits brought by the innovative drug pipeline but also plan...Open Technical Productization Collaboration Results to Academia and Industry, with the model of "computing power support + data development + ecological sharing", to jointly explore new blue ocean of commercial value.

This collaboration not only represents a strategic leap for Dongyangguang Pharmaceutical in fully embracing the "AI + robotics" R&D paradigm, but also serves as another strong validation of the commercial value of XtalPi's general-purpose AI platform within large pharmaceutical enterprises. It marks a milestone convergence of China's top pharmaceutical industry and cutting-edge AI technological capabilities.

The two companies will break the limitations of "data silos" in traditional pharmaceutical enterprises and the "high threshold" of AI algorithm development by empowering from the bottom with AI + robotics technology. They will comprehensively accelerate drug pipeline innovation and clinical transformation through an automated and intelligent drug R&D engine. At the same time, Dongyangguang Pharmaceutical's unique high-quality data and XtalPi's AI + robotics technology will jointly enhance the prediction accuracy and efficiency of AI models, forming a dual technical advantage of "data + algorithm." In the future, as the full life cycle AI drug R&D engine co-built by the two parties opens to the industry, this cooperation has the potential to reshape the global ecosystem of pharmaceutical R&D and pave the way for both parties to explore business models that convert data assets into AI products and "Model as a Service" (MaaS). “Pipeline + Platform” The dual-driver model can not only quickly generate short-term visible technical benefits but also provide support for the long-term returns of the innovative drug pipeline, injecting long-term momentum into the development of both parties' businesses.

● CloseInDongyang Light Pharmaceuticals ●

Sunshine Lake Pharma Co., Ltd. (Abbreviated stock name: Dongyang Sunshine Lake Pharma, Stock code: 06887.HK) was founded in 2003. It is a comprehensive pharmaceutical company driven by independent research and development, rooted in China, and oriented towards the world. Sunshine Lake Pharma provides innovative, high-quality, and affordable drugs to patients worldwide, with the corporate vision of becoming a world-class pharmaceutical company. Over the past 20 years, the company has adhered to the development strategies of "innovation" and "internationalization," establishing leading drug R&D platforms in China, production facilities that meet international standards, and a sales network covering the globe. The company strategically focuses on three key areas: infectious diseases, chronic diseases, and oncology. It has more than 150 approved drugs globally, over 100 drugs in the research pipeline, including nearly 50 first-class innovative drugs, gradually developing into one of the leading enterprises in China's biopharmaceutical industry. The company has been listed in the "Top 20 Comprehensive Ranking of China's Pharmaceutical R&D Strength" issued by PharmAI for seven consecutive years, entered the "Top 100 China Pharmaceutical R&D Strength Ranking 2025," and received numerous honors, including the First Prize of Guangdong Province Science and Technology Progress Award and the Gold Medal of China Patent Award.